You just read:

Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Sep 26, 2019, 14:10 ET